Impact of socioeconomic status on survival in patients with ovarian cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 10 2018
revised: 07 12 2018
accepted: 28 12 2018
pubmed: 4 2 2019
medline: 11 2 2020
entrez: 4 2 2019
Statut: ppublish

Résumé

Socioeconomic status may impact survival in cancer patients. This study assessed whether low socioeconomic status has an impact on survival in patients with ovarian cancer and investigated whether differences in survival may be explained by type of therapy received. The study population comprised 318 patients with ovarian cancer diagnosed between 2011 and 2015 in the François Baclesse regional cancer care center in Caen, North-West France. Socioeconomic status was assessed by using the European deprivation index and overall survival was calculated at 3 years. The unadjusted 3-year overall survival rate was 52% (95% CI 47 to 58). In a multivariable logistic regression model, a low socioeconomic status was associated with a lower probability of surgical resection (OR 0.34, 95% CI 0.16 to 0.74). A high socioeconomic status was associated with improved survival, adjusted for age, performance status, grade, and International Federation of Gynecology and Obstetrics (FIGO) stage (adjusted HR 1.53, 95% CI 1.04 to 2.26). When adjusting for treatment variables, there was no longer any significant difference in survival according to socioeconomic status (adjusted HR 1.24, 95% CI 0.83 to 1.84). Higher socioeconomic status is associated with a greater probability of undergoing surgical resection and with improved survival in patients with ovarian cancer.

Identifiants

pubmed: 30712018
pii: ijgc-2018-000097
doi: 10.1136/ijgc-2018-000097
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

792-801

Informations de copyright

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Joséphine Gardy (J)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France josephine.gardy@inserm.fr.
Calvados General Cancer Registry, Caen, France.
Calvados Digestive Cancer Registry, Caen, France.

Olivier Dejardin (O)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.
University Hospital of Caen, Caen, France.

Alexandre Thobie (A)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.

Yassine Eid (Y)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.

Anne-Valérie Guizard (AV)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.
Calvados General Cancer Registry, Caen, France.

Guy Launoy (G)

"ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.
Calvados Digestive Cancer Registry, Caen, France.
University Hospital of Caen, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH